very important (but negative) trial on cdk46i in mTNBC. huge shout-out to @stolaney1.bsky.social and Shom Goel for conducting this trial👍 @oncoalert.bsky.social #bcsm
📢 Just published! A phase II study of #abemaciclib for patients with #retinoblastoma-positive, triple-negative #metastatic breast cancer.
🔓https://pubmed.ncbi.nlm.nih.gov/39908010/
@drtimothyerick.bsky.social @nlinmd.bsky.social
@stolaney1.bsky.social
🔓https://pubmed.ncbi.nlm.nih.gov/39908010/
@drtimothyerick.bsky.social @nlinmd.bsky.social
@stolaney1.bsky.social
February 7, 2025 at 10:00 PM
very important (but negative) trial on cdk46i in mTNBC. huge shout-out to @stolaney1.bsky.social and Shom Goel for conducting this trial👍 @oncoalert.bsky.social #bcsm
A recent commentary challenges the use of CDK4/6i (abemaciclib/ribociclib) as adjuvant therapy for ER+ early BC. Despite approvals, their analysis highlights key concerns:
@ascocancer.bsky.social
#Onco404 #MedSky #OncSky #Cancer #Kanser #BreastCancer #MemeKanseri #CDK46i #ClinicalTrials
@ascocancer.bsky.social
#Onco404 #MedSky #OncSky #Cancer #Kanser #BreastCancer #MemeKanseri #CDK46i #ClinicalTrials
April 23, 2025 at 7:22 PM
A recent commentary challenges the use of CDK4/6i (abemaciclib/ribociclib) as adjuvant therapy for ER+ early BC. Despite approvals, their analysis highlights key concerns:
@ascocancer.bsky.social
#Onco404 #MedSky #OncSky #Cancer #Kanser #BreastCancer #MemeKanseri #CDK46i #ClinicalTrials
@ascocancer.bsky.social
#Onco404 #MedSky #OncSky #Cancer #Kanser #BreastCancer #MemeKanseri #CDK46i #ClinicalTrials